Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trialsFaı̈ez Zannad, Nicholas Ryan, Christopher M. O’Connor et al.|The Lancet|2025Cited by 39
Mechanistic evaluation of ertugliflozin in patients with type 2 diabetes and heart failureYuliya Lytvyn, David Z.I. Cherney, Rosalie A. Scholtes et al.|Physiological Reports|2025Cited by 5
Baseline Characteristic Of Participants In The Victor (Vericiguat Global Study In Participants With Chronic Heart Failure) Trial Global Study In Participants With Chronic Heart Failure) Trial:Faiez Zannad, Javed Butler, Stefano Corda et al.|Journal of Cardiac Failure|2025Cited by 0